

- Biofilm embedded staphylococcal infections are difficult to treat and there are limited effective therapeutic options; novel treatments including combination therapy are needed
- We evaluated several unique combinations of daptomycin (DAP) and vancomycin (VAN) with clarithromycin (CLA) or rifampin (RIF) against staphylococci with varying susceptibility to VAN (methicillin-resistant *Staphylococcus aureus*, hetero-resistant vancomycin intermediate *S. aureus* and methicillin-resistant coagulase-negative staphylococci) utilizing an *in vitro* biofilm reactor with titanium, teflon and steel materials
- Results demonstrated the most consistent killing with high-dose DAP in combination with RIF against all organisms tested
- RIF prevented the emergence of resistance to DAP or VAN in all organisms
- High-dose DAP in combination with RIF may be a viable option for medical device biofilm infections involving staphylococci

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Cubist Pharmaceuticals. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).